Clinical trial · Observational
[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
NCT00556153CI-TRIAL-00008813withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants ever enrolled.
Summary
Brief summary (as posted)
The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumors | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Phase I
- description
- Children, ages 5-15 years with brain tumors
- interventionNames
- Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
Primary outcomes (1)
- measure
- Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as measured by standardized uptake value and tumor/non-tumor uptake ratios
- timeFrame
- 15-30 minutes after IV administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including PNET, optic pathway glioma, brainstem glioma, ependymoma. Exclusion Criteria: * Pregnancy * Requirement for sedation * Lack of informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.